FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136366956> ?p ?o ?g. }

• W2136366956 endingPage "F1314" @default.
• W2136366956 startingPage "F1313" @default.
• W2136366956 abstract "EDITORIAL FOCUSDo calcimimetics directly alter bone remodeling?David GoltzmanDavid GoltzmanDepartments of Medicine and Physiology, McGill University and McGill University Health Centre, Montreal, CanadaPublished Online:01 Jun 2010https://doi.org/10.1152/ajprenal.00147.2010This is the final version - click for previous versionMoreSectionsPDF (39 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat secondary hyperparathyroidism is an almost inevitable consequence of untreated chronic kidney disease (CKD), resulting in disordered skeletal remodeling and mineralization defects. Thus, due to the high circulating levels of parathyroid hormone (PTH), both osteoblast and osteoclast surfaces may be augmented and ultimately bone volume may be reduced (11). In CKD, synthesis of 1,25 dihydroxyvitamin D [1,25(OH)2D] is impaired. This occurs at least in part due to suppression of renal 25-hydroxyvitamin D-1α-hydroxylase [the enzyme synthesizing 1,25(OH)2D] by retained phosphate and by elevated concentrations of FGF23 (16), and in part because of loss of renal parenchyma. As a consequence, low levels of 1,25(OH)2D develop in stage 3 CKD leading to reduced calcium absorption (1). The low 1,25(OH)2D and resultant hypocalcemia can lead to the development of secondary hyperparathyroidism mainly due to the fact that 1,25(OH)2D via the vitamin D receptor, and extracellular ionized calcium [Ca2+]e, by activating the calcium-sensing receptor (CaSR), coordinately regulates PTH biosynthesis and parathyroid cell growth. The CaSR is a G protein-coupled receptor that responds to [Ca2+]e in particular, but also to multiple extracellular cations (2). In addition to modulating parathyroid function, CaSR also regulates renal calcium reabsorption. More recently, CaSR has also been reported to function in vitro in a variety of skeletal cells, including osteoblasts, bone marrow stromal cells, monocyte macrophages, and osteoclasts (3). Furthermore, in vivo studies showed that transgenic mice with a constitutively active mutant CaSR targeted to mature osteoblasts demonstrate enhanced bone resorption (4), whereas mice with deletion of both CaSR and 25-hydroxyvitamin D-1α-hydroxylase exhibit reduced bone resorption (15). Other studies noted the importance of an alternate extracellular cation-sensing G protein-coupled receptor in bone and specifically in osteoblasts (13) and targeted deletion of the gene encoding this receptor has been reported to produce either osteopenia (14) or no skeletal phenotype (18).Calcimimetics are small orally active agents that act as positive allosteric modifiers of the CaSR. As type II agonists, they do not activate the receptor directly but instead increase receptor sensitivity to the type I agonists calcium and polycations (e.g., neomycin, gadolinium) (6). One such calcimimetic, the phenylalkylamine derivative cinacalcet HCl, has been approved for clinical use in the treatment of secondary hyperparathyroidism in CKD and in the treatment of parathyroid carcinoma.In the American Journal of Physiology-Renal Physiology, Finch and colleagues (5) report a comparison between cinacalcet and a potent analog of 1,25(OH)2D, paricalcitol, on bone and mineral metabolism in uremic rats. These animals have creatinine clearances “equivalent” to patients with CKD 3–4 and manifest secondary hyperparathyroidism. Although both agents suppressed elevated serum PTH levels, among their findings was that bone resorption was increased and bone volume was reduced after treatment with cinacalcet. This observation has great translational importance because a direct negative effect of calcimimetics on the skeleton would be of major concern for the use of these agents to control parathyroid disease.What can we learn from the existing literature that may help in placing this observation in context? Using the phenylalkylamine derivative NPS R-568 that acts as an agonist at the CaSR, it has been reported that peritrabecular fibrosis in bone of uremic rats with secondary hyperparathryoidism was reduced and that volumetric cortical bone mineral density (BMD) was improved (17). Nevertheless, the elevated osteoclast and osteoblast surfaces characteristic of hyperparathyroidism which were observed in these animals were not significantly reduced by this calcimimetic even though PTH was reduced. In a more recent study using the arylalkylamine calcimimetic AMG 641 in an adenine-induced uremic rat model of secondary hyperparathyroidism, reductions in trabecular bone volume and trabecular number and increases in trabecular spacing were prevented. Again, however, although osteoblast surface/bone surface was significantly decreased, consistent with the decrease in secondary hyperparathyroidism induced by the calcimimetic, there were no significant decreases in bone resorption (osteoclast surface/bone surface) (7).What has been the experience in humans? In a year-long placebo-controlled trial in patients with primary hyperparathyroidism, cinacalcet administration increased biomarkers of bone turnover (although they remained in the normal range) despite a drop of ∼20% in serum PTH levels. Furthermore, there were no positive effects on BMD after 1 yr compared with placebo (12). Several small studies in hemodialysis patients (8–10, 19) have now demonstrated that as cinacalcet treatment decreases circulating PTH levels, cinacalcet may also decrease biomarkers of bone turnover. However, most of these studies may have been confounded by the concurrent use of vitamin D and/or phosphate binders in the treatment of these patients.Clearly therefore, the work of Finch et al. (5) on the resorptive effects of cinacalcet on the skeleton needs first to be confirmed in further animal studies. Additionally, the mechanism of action of calcimimetics in bone needs to be clarified; that is, whether this effect occurs via the CaSR, some other skeletal calcium receptor, or some other direct or indirect mechanism. Finally, the skeletal effect of cinacalcet in humans needs to be clarified in larger studies of patients with CKD and renal osteodystrophy. Overall, such studies should shed light on important new physiology of bone remodeling but would also be paramount in clarifying the therapeutic role of what has become an important part of our armamentarium for managing hyperparathyroidism.DISCLOSURESD. Goltzman acted as a consultant to Amgen, Genzyme, Lilly, Merck, and Novartis.REFERENCES1. Andress DL , Coyne DW , Kalantar-Zadeh K , Molitch ME , Zangeneh F , Sprague SM. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract 14: 18–27, 2008.Crossref | PubMed | Google Scholar2. Brown EM , Gamba G , Riccardi D , Lombardi M , Butters R , Kifor O , Sun A , Hediger MA , Lytton J , Hebert SC. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 366: 575–580, 1993.Crossref | PubMed | ISI | Google Scholar3. Chang W , Tu C , Chen TH , Komuves L , Oda Y , Pratt SA , Miller S , Shoback D. Expression and signal transduction of calcium-sensing receptors in cartilage and bone. Endocrinology 140: 5883–5893, 1999.Crossref | PubMed | ISI | Google Scholar4. Dvorak MM , Chen TH , Orwoll B , Garvey C , Chang W , Bikle DD , Shoback DM. Constitutive activity of the osteoblast Ca2+-sensing receptor promotes loss of cancellous bone. Endocrinology 148: 3156–3163, 2007.Crossref | PubMed | ISI | Google Scholar5. Finch JL , Tokumoto M , Nakamura H , Yao W , Shahnazari M , Lane N , Slatopolsky E. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol (doi:10.1152/ajprenal.00522.2009).ISI | Google Scholar6. Hebert SC. Therapeutic use of calcimimetics. Annu Rev Med 57: 349–364, 2006.Crossref | PubMed | ISI | Google Scholar7. Henley C , Davis J , Miller G , Shatzen E , Cattley R , Li X , Martin D , Yao W , Lane N , Shalhoub V. The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. Eur J Pharmacol 616: 306–313, 2009.Crossref | PubMed | ISI | Google Scholar8. Jean G , Chazot C , Charra B. 12 Months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Clin Nephrol 68: 63–64, 2007.Crossref | PubMed | ISI | Google Scholar9. Lien YH , Silva AL , Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 20: 1232–1237, 2005.Crossref | PubMed | ISI | Google Scholar10. Malluche HH , Monier-Faugere MC , Wang G , Frazã OJM , Charytan C , Coburn JW , Coyne DW , Kaplan MR , Baker N , McCary LC , Turner SA , Goodman WG. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69: 269–278, 2008.Crossref | PubMed | ISI | Google Scholar11. Ott SM. Bone histomorphometry in renal osteodystrophy. Semin Nephrol 29: 122–132, 2009.Crossref | PubMed | ISI | Google Scholar12. Peacock M , Bilezikian JP , Klassen PS , Guo MD , Turner SA , Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90: 135–141, 2005.Crossref | PubMed | ISI | Google Scholar13. Pi M , Faber P , Ekema G , Jackson PD , Ting A , Wang N , Fontilla-Poole M , Mays RW , Brunden KR , Harrington JJ , Quarles LD. Identification of a novel extracellular cation-sensing G protein-coupled receptor. J Biol Chem 280: 40201–40209, 2005.Crossref | PubMed | ISI | Google Scholar14. Pi M , Chen L , Huang MZ , Zhu W , Ringhofer B , Luo J , Christenson L , Li B , Zhang J , Jackson PD , Faber P , Brunden KR , Harrington JJ , Quarles LD. GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS One 3: e3858, 2008.Crossref | PubMed | ISI | Google Scholar15. Richard C , Huo R , Samadfam R , Bolivar I , Miao D , Brown EM , Hendy GN , Goltzman D. The calcium sensing receptor and 25-hydroxyvitamin D-1α-hydroxylase interact to modulate skeletal growth and bone turnover. J Bone Miner Res In press.ISI | Google Scholar16. Shimada T , Yamazaki Y , Takahashi M , Hasegawa H , Urakawa I , Oshima T , Ono K , Kakitani M , Tomizuka K , Fujita T , Fukumoto S , Yamashita T. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289: F1088–F1095, 2005.Link | ISI | Google Scholar17. Wada M , Ishii H , Furuya Y , Fox J , Nemeth EF , Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53: 448–453, 1998.Crossref | PubMed | ISI | Google Scholar18. Wellendorph P , Johansen L , Jensen A , Casanova E , Gassmann M , Deprez P , Clement-Lacroix P , Bettler B , Bräuner-Osborne H. No evidence for a bone phenotype in GPRC6A knockout mice under normal physiological conditions. J Mol Endocrinol 42: 215–223, 2009.Crossref | PubMed | ISI | Google Scholar19. Yajima A , Akizawa T , Tsukamoto Y , Kurihara S , Ito A K Study Group. Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism. Ther Apher Dial 12, Suppl 1: S38–S43, 2008.Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESAddress for reprint requests and other correspondence: D. Goltzman, Calcium Research Laboratory, Royal Victoria Hospital, Rm H467, 687 Pine Ave., Montreal, QC, H3A 1A1 Canada (e-mail: david.[email protected]ca). Download PDF Previous Back to Top Next FiguresReferencesRelatedInformation Cited ByPrimary Hyperparathyroidism in the Pediatric Patient16 December 2016Primary Hyperparathyroidism in Children and AdolescentsPrimary hyperparathyroidism in children and adolescentsJournal of the Chinese Medical Association, Vol. 75, No. 9 More from this issue > Volume 298Issue 6June 2010Pages F1313-F1314 Copyright & PermissionsCopyright © 2010 the American Physiological Societyhttps://doi.org/10.1152/ajprenal.00147.2010PubMed20237238History Published online 1 June 2010 Published in print 1 June 2010 Metrics" @default.
• W2136366956 created "2016-06-24" @default.
• W2136366956 creator A5030199838 @default.
• W2136366956 date "2010-06-01" @default.
• W2136366956 modified "2023-09-26" @default.
• W2136366956 title "Do calcimimetics directly alter bone remodeling?" @default.
• W2136366956 cites W2009441758 @default.
• W2136366956 cites W2017218776 @default.
• W2136366956 cites W2032916864 @default.
• W2136366956 cites W2035131199 @default.
• W2136366956 cites W2035726600 @default.
• W2136366956 cites W2042922859 @default.
• W2136366956 cites W2050935798 @default.
• W2136366956 cites W2064584518 @default.
• W2136366956 cites W2093535035 @default.
• W2136366956 cites W2099363221 @default.
• W2136366956 cites W2102807893 @default.
• W2136366956 cites W2105398326 @default.
• W2136366956 cites W2116294269 @default.
• W2136366956 cites W2135000638 @default.
• W2136366956 cites W2155158886 @default.
• W2136366956 cites W2169280749 @default.
• W2136366956 cites W2328247080 @default.
• W2136366956 doi "https://doi.org/10.1152/ajprenal.00147.2010" @default.
• W2136366956 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20237238" @default.
• W2136366956 hasPublicationYear "2010" @default.
• W2136366956 type Work @default.
• W2136366956 sameAs 2136366956 @default.
• W2136366956 citedByCount "4" @default.
• W2136366956 countsByYear W21363669562012 @default.
• W2136366956 countsByYear W21363669562015 @default.
• W2136366956 countsByYear W21363669562016 @default.
• W2136366956 countsByYear W21363669562020 @default.
• W2136366956 crossrefType "journal-article" @default.
• W2136366956 hasAuthorship W2136366956A5030199838 @default.
• W2136366956 hasBestOaLocation W21363669562 @default.
• W2136366956 hasConcept C12021080 @default.
• W2136366956 hasConcept C126322002 @default.
• W2136366956 hasConcept C170033053 @default.
• W2136366956 hasConcept C170493617 @default.
• W2136366956 hasConcept C2776033226 @default.
• W2136366956 hasConcept C71924100 @default.
• W2136366956 hasConceptScore W2136366956C12021080 @default.
• W2136366956 hasConceptScore W2136366956C126322002 @default.
• W2136366956 hasConceptScore W2136366956C170033053 @default.
• W2136366956 hasConceptScore W2136366956C170493617 @default.
• W2136366956 hasConceptScore W2136366956C2776033226 @default.
• W2136366956 hasConceptScore W2136366956C71924100 @default.
• W2136366956 hasIssue "6" @default.
• W2136366956 hasLocation W21363669561 @default.
• W2136366956 hasLocation W21363669562 @default.
• W2136366956 hasLocation W21363669563 @default.
• W2136366956 hasOpenAccess W2136366956 @default.
• W2136366956 hasPrimaryLocation W21363669561 @default.
• W2136366956 hasRelatedWork W1498025464 @default.
• W2136366956 hasRelatedWork W196227859 @default.
• W2136366956 hasRelatedWork W1965696823 @default.
• W2136366956 hasRelatedWork W1973661281 @default.
• W2136366956 hasRelatedWork W2166266977 @default.
• W2136366956 hasRelatedWork W2283105156 @default.
• W2136366956 hasRelatedWork W2412080961 @default.
• W2136366956 hasRelatedWork W2997598020 @default.
• W2136366956 hasRelatedWork W4317211277 @default.
• W2136366956 hasRelatedWork W58754261 @default.
• W2136366956 hasVolume "298" @default.
• W2136366956 isParatext "false" @default.
• W2136366956 isRetracted "false" @default.
• W2136366956 magId "2136366956" @default.
• W2136366956 workType "article" @default.